Ryoichi Miyazaki

614 total citations
23 papers, 275 citations indexed

About

Ryoichi Miyazaki is a scholar working on Surgery, Nephrology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ryoichi Miyazaki has authored 23 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Nephrology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ryoichi Miyazaki's work include Parathyroid Disorders and Treatments (3 papers), Iron Metabolism and Disorders (3 papers) and Dialysis and Renal Disease Management (3 papers). Ryoichi Miyazaki is often cited by papers focused on Parathyroid Disorders and Treatments (3 papers), Iron Metabolism and Disorders (3 papers) and Dialysis and Renal Disease Management (3 papers). Ryoichi Miyazaki collaborates with scholars based in Japan, Switzerland and United States. Ryoichi Miyazaki's co-authors include Fumitake Gejyo, Hideki Kimura, Kyoko Miyagi, Y Tofuku, Satoru Suzuki, R Takeda, Masahiro Kuroda, Takashi Akiyama, Haruyoshi Yoshida and Satoru Suzuki and has published in prestigious journals such as Scientific Reports, Kidney International and Journal of the American Society of Nephrology.

In The Last Decade

Ryoichi Miyazaki

20 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryoichi Miyazaki Japan 9 125 67 59 56 55 23 275
Despina Kyriaki Greece 10 83 0.7× 39 0.6× 86 1.5× 55 1.0× 39 0.7× 24 329
Emanuele De Simone Italy 10 210 1.7× 42 0.6× 28 0.5× 31 0.6× 26 0.5× 28 361
Abdullah Şumnu Türkiye 8 101 0.8× 48 0.7× 25 0.4× 47 0.8× 11 0.2× 36 231
Hidehiko Kashiwabara Japan 10 98 0.8× 72 1.1× 15 0.3× 39 0.7× 20 0.4× 36 284
Zbigniew Hruby Poland 9 112 0.9× 50 0.7× 17 0.3× 56 1.0× 16 0.3× 32 282
Yuko Shibuya Japan 10 34 0.3× 46 0.7× 34 0.6× 32 0.6× 25 0.5× 23 239
Cengiz Candan Türkiye 12 211 1.7× 52 0.8× 20 0.3× 36 0.6× 19 0.3× 29 390
J Klassen Canada 10 133 1.1× 100 1.5× 17 0.3× 53 0.9× 14 0.3× 22 345
Onur Sakallıoğlu Türkiye 8 27 0.2× 71 1.1× 24 0.4× 22 0.4× 50 0.9× 24 250
R. Goucha Tunisia 10 123 1.0× 90 1.3× 13 0.2× 38 0.7× 9 0.2× 62 346

Countries citing papers authored by Ryoichi Miyazaki

Since Specialization
Citations

This map shows the geographic impact of Ryoichi Miyazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryoichi Miyazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryoichi Miyazaki more than expected).

Fields of papers citing papers by Ryoichi Miyazaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryoichi Miyazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryoichi Miyazaki. The network helps show where Ryoichi Miyazaki may publish in the future.

Co-authorship network of co-authors of Ryoichi Miyazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Ryoichi Miyazaki. A scholar is included among the top collaborators of Ryoichi Miyazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryoichi Miyazaki. Ryoichi Miyazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miyazaki, Ryoichi, et al.. (2023). Robust antibody response after the third mRNA coronavirus vaccination in Japanese hemodialysis patients. Renal Replacement Therapy. 9(1). 1 indexed citations
2.
Miyazaki, Ryoichi & Kyoko Miyagi. (2023). Oral semaglutide in kidney transplant recipients with metabolic syndrome: three Japanese cases. Renal Replacement Therapy. 9(1). 3 indexed citations
3.
Miyazaki, Ryoichi, et al.. (2023). Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients. Renal Replacement Therapy. 9(1). 13–13. 3 indexed citations
4.
Miyazaki, Ryoichi & Kyoko Miyagi. (2022). Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. BMC Nephrology. 23(1). 168–168. 6 indexed citations
5.
Yokoyama, Keitaro, Ryutaro Shimazaki, Masafumi Fukagawa, et al.. (2019). Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Scientific Reports. 9(1). 6410–6410. 16 indexed citations
6.
Miyazaki, Ryoichi, et al.. (2019). Three patients undergoing maintenance hemodialysis presented with hypocupremic hematological abnormalities during the administration of zinc acetate. Nihon Toseki Igakkai Zasshi. 52(3). 177–184. 1 indexed citations
7.
Ito, Kiyoaki, Satoshi Hara, Kazunori Yamada, et al.. (2019). A case report of crystalline light chain inclusion-associated kidney disease affecting podocytes but without Fanconi syndrome. Medicine. 98(5). e13915–e13915. 8 indexed citations
8.
Miyazaki, Ryoichi & Kyoko Miyagi. (2016). Effect and Safety of Daclatasvir‐Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b ‐Infected Patients on Hemodialysis. Therapeutic Apheresis and Dialysis. 20(5). 462–467. 19 indexed citations
9.
10.
Gejyo, Fumitake, Yoshindo Kawaguchi, Shigeko Hara, et al.. (2004). Arresting Dialysis‐Related Amyloidosis: A Prospective Multicenter Controlled Trial of Direct Hemoperfusion with a β2‐Microglobulin Adsorption Column. Artificial Organs. 28(4). 371–380. 30 indexed citations
11.
Kimura, Hideki, et al.. (2003). Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney International. 64(5). 1829–1837. 37 indexed citations
12.
Kimura, Hideki, et al.. (2000). A C677T mutation in the methylenetetrahydrofolate reductase gene modifies serum cysteine in dialysis patients. American Journal of Kidney Diseases. 36(5). 925–933. 9 indexed citations
13.
Kimura, Hideki, Fumitake Gejyo, Satoru Suzuki, & Ryoichi Miyazaki. (2000). The C677T Methylenetetrahydrofolate Reductase Gene Mutation in Hemodialysis Patients. Journal of the American Society of Nephrology. 11(5). 885–893. 37 indexed citations
14.
Kimura, Hideki, Fumitake Gejyo, Tomoko Yamaguchi, et al.. (1999). A Cholesteryl Ester Transfer Protein Gene Mutation and Vascular Disease in Dialysis Patients. Journal of the American Society of Nephrology. 10(2). 294–299. 15 indexed citations
15.
Araki, Hideo, et al.. (1997). A case of diabetic ketoacidosis in a hemodialysis patient.. Nihon Toseki Igakkai Zasshi. 30(4). 265–269. 1 indexed citations
16.
Araki, Hideo, et al.. (1997). Antineutrophil cytoplasmic antibody-positive rapidly progressive glomerulonephritis caused by propylthiouracil: A case report. Clinical and Experimental Nephrology. 1(3). 225–228. 5 indexed citations
17.
Miyamori, Isamu, et al.. (1989). Falsely elevated plasma aldosterone concentration by direct radioimmunoassay in chronic renal failure.. PubMed. 114(3). 294–300. 12 indexed citations
18.
Koni, Ichiro, Masao Kawai, Akitoshi Nakashima, et al.. (1987). [Three cases of rheumatoid arthritis developing glomerulonephritis with crescent formation].. PubMed. 29(4). 477–83. 1 indexed citations
19.
Tofuku, Y, Ryoichi Miyazaki, Ichiro Koni, et al.. (1986). Treatment of vascular calcification and lipid disorders in hemodialysis patients with elastase. Journal of Japanese Society for Dialysis Therapy. 19(6). 549–557. 1 indexed citations
20.
Miyazaki, Ryoichi, et al.. (1984). Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy.. Clinical Nephrology. 21(6). 335–40. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Despina Kyriaki Breakdown of academic impact, for papers by Emanuele De Simone Breakdown of academic impact, for papers by Abdullah Şumnu Breakdown of academic impact, for papers by Hidehiko Kashiwabara Breakdown of academic impact, for papers by Zbigniew Hruby Breakdown of academic impact, for papers by Yuko Shibuya Breakdown of academic impact, for papers by Cengiz Candan Breakdown of academic impact, for papers by J Klassen Breakdown of academic impact, for papers by Onur Sakallıoğlu Breakdown of academic impact, for papers by R. Goucha
Rankless by CCL
2026